Evaluation of conjugated estrogen plus medroxyprogesterone acetate versus tibolone in early postmenopausal Chinese women

Chinese Medical Journal (Taipei)

Volumn 62, Issue 5, 1999, Pages 308-315

  Yang, Tzay Shing ^a   Tsan, Shun Hwa ^a   Chen, Chung Rong ^a   Chang, Sheng Ping ^a   Yuan, Chiou Chung ^a  

^a NONE

Author keywords

Hormone replacement therapy; Menopause; Tibolone

Indexed keywords

CONJUGATED ESTROGEN; FOLLITROPIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; TIBOLONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; CHINA; CLIMACTERIUM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HORMONE SUBSTITUTION; HUMAN; LIPID BLOOD LEVEL; LUMBAR SPINE; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SPOTTING;

BONE DENSITY; ENDOMETRIUM; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; LIPIDS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; NORPREGNENES;

EID: 0032999401     PISSN: 05781337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Manpower Planning Department. Projections of the Population of the Taiwan Area, ROC. Taipei: Manpower Planning Department. May 1991:1990-2036.
2. van der Vies J. Pharmacological studies with (7aa, 17aa)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-One (Org OD 14). Maturitas 1987;(Suppl 1): 15-24.
3. Benedek-Jaszmann LJ. Long-term placebo-controlled efficacy and safety study of Org OD 14 in climacteric women. Maturitas 1987;(Suppl 1):25-33.
4. Genazzani AR, Facchinetti F, Petraglia F. Effects of Org 14 on pituitary and peripheral β-endorphins in castrated rats and in postmenopausal women. Maturitas 1987;(Suppl 1): 35-48.
5. Netelenbos JC, Siregar-Emk MTW, Schot LPC, Van Ginkel FC, Lips P, Leeuwenkamp OR. Short-term effects of Org OD 14 and 17bb-estradiol on bone and lipid metabolism in early post-menopausal women. Maturitas 1991;13:137-49.
6. Geusens P, Dequeker J, Gielen J, Schot LPC. Non-linear increase of vertebral density by a synthetic steroid (Org OD 14) in established osteoporosis. Maturitas 1991;13: 155-62.
7. Rymer J, Chapman MG, Fogelman I. Effect of tibolone on postmenopausal bone loss. Osteoporos Int 1994;4:314-9.
8. Genazzani AR, Benedek-Jaszmann LJ, Hart DM, Andolsel L, Kicovic PM, Tax L. Org OD 14 and the endometnum. Maturitas 1991;13:243-51.
9. Volpe A, Facchinetti F, Grasso A, Petraglia F, Campanini D, Genazzani AR. Benefits and risks of different hormonal replacement therapies in postmenopausal women. Maturitas 1986;8:327-34.
10. Greene JG. The social and psychological origins of the climacteric syndrome. In: Greene JG. Methodological Issues in Climacteric Research. Gower: Aldershot Hants, 1984.
11. Ravnilar VA. Compliance with hormone therapy. Am J Obstet Gynecol 1987;156:1332-4.
12. Nachtigall LE. Enhancing patient compliance with hormone replacement therapy at menopause. Obstet Gynecol 1990;75(Suppl 4):775-805.
13. Lindsay R, Aitken JM, Anderson JB, Hart DM, MacDonald EB, Clarke AC. Long-term prevention of postmenopausal osteoporosis by oestrogen. Lancet 1976;1:1038-41.
14. Trevoux R, Dieulangard P, Blum A. Efficacy and safety of Org OD 14 in the treatment of climacteric complaints. Maturitas 1983;5:89-96.
15. Yang TS, Tsan SH, Chang SP, Ng HT. Efficacy and safety of estriol replacement therapy for climacteric women. Chin Med J (Taipei) 1995;55:386-91.
16. Millner MH. A 2-year study of lipid and lipoprotein changes in postmenopausal women with tibolone and estrogen-progestin. Obstet Gynecol 1996;87:593-9.
17. Wakatsuki A, Ikenoue N, Sagara Y. Estrogen-induced small, low-density lipoprotein particles in postmenopausal women. Obstet Gynecol 1998;91:234-40.